Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK575385PMID: 34813257
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 110766-97-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of lusutrombopag during breastfeeding. The manufacturer recommends avoiding breastfeeding during the use of lusutrombopag and for at least 28 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Lusutrombopag
CAS Registry Number
1110766-97-6
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.[Health Technol Assess. 2020]Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, Swift S, Drachen T, Raatz H, Ryder S, et al. Health Technol Assess. 2020 Oct; 24(51):1-220.
- Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.[JA Clin Rep. 2018]Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.Sasaguri T, Hirakawa N, Uemura S. JA Clin Rep. 2018 Nov 20; 4(1):80. Epub 2018 Nov 20.
- Review Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.[Drugs. 2019]Review Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.Shirley M, McCafferty EH, Blair HA. Drugs. 2019 Oct; 79(15):1689-1695.
- Lusutrombopag: First Global Approval.[Drugs. 2016]Lusutrombopag: First Global Approval.Kim ES. Drugs. 2016 Jan; 76(1):155-8.
- Review Avatrombopag.[Drugs and Lactation Database (...]Review Avatrombopag.. Drugs and Lactation Database (LactMed®). 2006
- Lusutrombopag - Drugs and Lactation Database (LactMed®)Lusutrombopag - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...